Cost-effectiveness of cervical-cancer screening in five developing countries

New England Journal of Medicine

Volumn 353, Issue 20, 2005, Pages 2158-2168

  Goldie, Sue J ^a   Gaffikin, Lynne ^b   Goldhaber Fiebert, Jeremy D ^c   Gordillo Tobar, Amparo ^d   Levin, Carol ^e   Mahé, Cédric ^f   Wright, Thomas C ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b JHPIEGO   (United States)

^c HARVARD UNIVERSITY   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Prog Appropriate Technol Hlth   (United States)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g Harvard University Initiative for Global Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID;

ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; CYTOLOGY; DATA ANALYSIS; DEVELOPING COUNTRY; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; INDIA; KENYA; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERU; PRIORITY JOURNAL; SOUTH AFRICA; THAILAND; TUMOR BIOPSY; UTERINE CERVIX; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DNA, VIRAL; FEMALE; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 27844511931     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa044278     Document Type: Article

References (29)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancerbase no. 5. Lyon, France: IARC Press, 2001.
2. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001;79:954-62.
3. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC Jr. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000;89:826-33.
4. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary care setting: University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 1999;353:869-73.
5. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
6. Sankaranarayanan R, Shyamalakumary B, Wesley R, Sreedevi Amma N, Parkin DM, Nair MK. Visual inspection with acetic acid in the early detection of cervical cancer and precursors. Int J Cancer 1999;80:161-3.
7. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
8. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus type 16 and 18 in young women: a randomised control trial. Lancet 2004;364:1757-65.
9. World Bank WDI Online. (Accessed October 24, 2005, at http://www.worldbank.org/data/countrydata/countrydata.html.)
10. Women and men in the informal economy: a statistical picture. International Labour Office Report. (Accessed October 24, 2005, at: http://www.ilo.org/public/english/employment/gems/download/women.pdf.)
11. Department of Commerce. 1999 Income data. (Accessed October 24, 2005, at http://ia.ita.doc.gov/wages/99wages/99wages.htm.)
12. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15. [Erratum, JAMA 2001;286:1026.]
13. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002;94:1469-83.
14. Disease Control Priorities Project guidelines. (Accessed October 24, 2005, at http://www.fic.nih.gov/dcpp/authors.html.)
15. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
16. World Health Organization. Life tables for 191 countries. (Accessed October 24, 2005, at http://www3.who.int/whosis/life_tables/life_tables_process. cfm?country=tcd&language=en.)
17. Future directions in epidemiologic and preventive research on human papillomavirus and cancer. In: Bosch FX, Schiffman M, Solomon D, eds. National Cancer Institute monograph no. 31. Bethesda, Md.: National Cancer Institute, 2003.
18. Alliance for Cervical Cancer Prevention (ACCP). Effectiveness, safety, and acceptability of cryotherapy: a systematic literature review. (Accessed October 24, 2005, at http://www.alliance-cxca.org/english/publications. html#presentations.)
19. World Health Organization statistical information system: CHOICE (CHOosing Interventions that are Cost Effective). (Accessed October 24, 2005, at http://www3.who.int/whosis/.)
20. Department of Labor. Wages, benefits, poverty line, and meeting workers' needs in the apparel and footwear industries of selected countries. (Accessed October 24, 2005, at http://www.dol.gov/ilab/media/reports/oiea/wagestudy/ wagestudy.pdf.)
21. Nominal interbank exchange rates (year averages). (Accessed October 24, 2005, at http://www.oanda.com/convert/fxhistory.)
22. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Effectiveness and Resource Allocation 2003;1:1. (Accessed October 24, 2005, at http://www.resource-allocation.com/ content/1/1/1.)
23. International Center for Tropical Agriculture. Accessibility, transport and travel time information. (Accessed October 24, 2005, at http://gisweb.ciat. cgiar.org/cross_scale/download/2.5_web.pdf.)
24. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-25.
25. van Ballegooijen M, Koopmanschap M, Tjokrowardojo AJ, van Oortmarssen GJ. Care and costs of advanced cervical cancer. Eur J Cancer 1992;28A:1703-8.
26. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001.
27. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003;38:215-22.
28. Wiseman V, Hawley WA, ter Kuile F, et al. The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya. Am J Trop Med Hyg 2003;68:Suppl 4:161-7.
29. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002;359:1980-9.